PingAn Good Doctor Partners with Roche and OrigiMed at CIIE
The 5th China International Import Expo (CIIE) saw China-based Ping An Healthcare and Technology Co.,...
Roche
Hua Medicine Launches Dorzagliatin, a First-in-Class Diabetes Drug, in China
China-based Hua Medicine has announced the commercial launch of its Category 1 drug, dorzagliatin, with...
Zhejiang Medicine’s ARX788 Advances to Phase II Study for HER2-Positive Cholangiocarcinoma
China-based Zhejiang Medicine Co., Ltd (SHA: 600216) has received approval from the National Medical Products...
Roche Reports Q3 Sales Growth, Hit by COVID-19 Product Decline
Swiss pharmaceutical giant Roche (SWX: ROG) released its Q3 2022 financial report last week, showing...
Hainan Poly Pharm’s Generic Ganciclovir Approved in Sweden for CMV Retinitis
China-based Hainan Poly Pharm Co., Ltd (SHE: 300630) has announced receiving technical review approval from...
Bio-Thera’s BAT1806 Biosimilar Accepted for Review by European Medicine Agency
China-based Bio-Thera Solutions Ltd (SHA: 688177) has announced that a Biologic License Application (BLA) for...
CSPC’s Generic Xofluza Gains NMPA Approval Amid Roche Patent Dispute
China-based CSPC Pharmaceutical Group Co., Ltd (HKG: 1093) has obtained market approval from the National...
Roche’s Subcutaneous Herceptin Approved in China for HER2-Positive Breast Cancer
Swiss pharmaceutical giant Roche’s (SWX: ROG) Herceptin (trastuzumab, subcutaneous injection) has been approved in China...
Roche Boosts China Investment with Additional RMB 250 Million
Swiss pharmaceutical giant Roche (SWX: ROG) has pledged to invest an additional RMB 250 million...
Ascletis Pharma and Roche Terminate Promotion Agreement for Pegasys
China-based Ascletis Pharma Inc. (HKG: 1672) has announced a supplementary agreement with Swiss pharmaceutical giant...
Shanghai Pharma’s CD20 Antibody Advances to Primary Nephropathy Trial After NMPA Approval
China’s Shanghai Pharmaceuticals (HKG: 2607, SHA: 601607) has received approval from the National Medical Products...
CSPC Pharmaceutical’s Mitoxantrone Liposome Approved for NMOSD Clinical Study
China-based CSPC Pharmaceutical Group Ltd (HKG: 1093) announced that its mitoxantrone hydrochloride liposome has received...
Jemincare Licenses Oral Androgen Receptor Degrader to Roche’s Genentech
China-based Jiangxi Jemincare Group has entered into a licensing agreement with Swiss giant Roche’s Genentech....
Henlius Biotech’s HanBeiTai sBLA Accepted for HCC Treatment Review
Shanghai Henlius Biotech Inc. (HKG: 2696) announced that a supplementary Biologic License Application (sBLA) for...
Roche’s Rozlytrek Wins NMPA Approval for ROS1+ NSCLC Treatment
Swiss pharmaceutical giant Roche’s China unit announced that it has received market approval from the...
NMPA Accepts Roche’s Crovalimab Filing for PNH Treatment with Priority Review
The National Medical Products Administration (NMPA) has officially accepted for review the market filing submitted...
Roche’s Rozlytrek Wins NMPA Approval for NTRK Fusion Gene-Positive Tumors
Swiss pharmaceutical giant Roche announced that it has received marketing approval from the National Medical...
Henlius Biotech’s HanBeiTai Biosimilar of Avastin Accepted for CDE Review
Shanghai Henlius Biotech Inc. (HKG: 2696) announced that the Center for Drug Evaluation (CDE) has...
Roche’s Chugai Launches Edirol in China for Postmenopausal Osteoporosis
Swiss pharma giant Roche’s subsidiary Chugai Pharmaceutical Co Ltd has officially launched Edirol (eldecalcitol), an...
CDE Grants Priority Review to Ascentage’s Olerembatinib and Roche’s Crovalimab
The Center for Drug Evaluation (CDE) has granted priority review status to two drugs: Suzhou...